Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Clin Ther. 2019 Mar 28;41(4):656–674.e4. doi: 10.1016/j.clinthera.2019.03.002

Figure 5.

Figure 5.

Predicted ME/CFS states associated with favorable response to treatment by A) rintatolimod or B) rituximab. The subset of models found to reach states with a distance-from-health of 0 (rintatolimod) or less than 50 (rituximab) under drug treatment were canvassed for their predictions of resting ME/CFS values for unconstrained network entities.